haloperidol has been researched along with Impaired Glucose Tolerance in 4 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Medication-naïve patients with schizophrenia (n = 99) underwent baseline fasting and 2 h post-prandial plasma glucose measurements repeated after 6 weeks after randomization to receive olanzapine, risperidone or haloperidol." | 5.13 | Diabetes and schizophrenia - effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia. ( Akhtar, S; Ameen, S; Manjunatha, N; Saddichha, S, 2008) |
| "To examine quantitatively the association between glucose intolerance including diabetes mellitus and the use of the atypical antipsychotics clozapine, olanzapine or risperidone, and to identify possible risk factors for the development of glucose intolerance during treatment with these drugs." | 3.71 | Glucose intolerance with atypical antipsychotics. ( Hägg, S; Hedenmalm, K; Mortimer, O; Spigset, O; Ståhl, M, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| García-Tornadú, I | 1 |
| Ornstein, AM | 1 |
| Chamson-Reig, A | 1 |
| Wheeler, MB | 1 |
| Hill, DJ | 1 |
| Arany, E | 1 |
| Rubinstein, M | 1 |
| Becu-Villalobos, D | 1 |
| Mandhane, S | 1 |
| Nayak, P | 1 |
| Soni, D | 1 |
| Jain, S | 1 |
| Ashton, JC | 1 |
| Rajamannar, T | 1 |
| Hedenmalm, K | 1 |
| Hägg, S | 1 |
| Ståhl, M | 1 |
| Mortimer, O | 1 |
| Spigset, O | 1 |
| Saddichha, S | 1 |
| Manjunatha, N | 1 |
| Ameen, S | 1 |
| Akhtar, S | 1 |
1 trial available for haloperidol and Impaired Glucose Tolerance
| Article | Year |
|---|---|
Diabetes and schizophrenia - effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus; Dose-Response Relationship, Drug; D | 2008 |
3 other studies available for haloperidol and Impaired Glucose Tolerance
| Article | Year |
|---|---|
Disruption of the dopamine d2 receptor impairs insulin secretion and causes glucose intolerance.
Topics: Analysis of Variance; Animals; Blood Glucose; Cabergoline; Cell Proliferation; Dopamine Agonists; Do | 2010 |
Induction of glucose intolerance by acute administration of rimonabant.
Topics: Administration, Oral; Animals; Benzoxazines; Blood Glucose; Dopamine Antagonists; Eating; Fenclonine | 2012 |
Glucose intolerance with atypical antipsychotics.
Topics: Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Bayes Theorem; Benzodiazepines; Chlor | 2002 |